6 completed. 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
Follow Basal Insulin: new trials by email Literature Review of Basal Insulin trials Research Report on Basal Insulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Afrezza® INHALE-1 Study in Pediatrics Afrezza, Rapid-acting Insulin Analog, Basal Insulin - Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Mannkind Corporation | 319 | 2021-09-29 | 2025-05-06 |
| A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007). Ertugliflozin 5 mg, Ertugliflozin 15 mg, Placebo to Ertugliflozin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 621 | 2013-12-13 | 2018-09-10 |
| Efficacy and Safety of FIAsp in a Basal-bolus Regimen Versus Basal Insulin Therapy, Both in Combination With Metformin in Adult Subjects With Type 2 Diabetes Faster-acting insulin aspart, basal insulin - Diabetes, Diabetes Mellitus, Type 2 | Phase 3 | Completed | Novo Nordisk A/S | 323 | 2013-09-23 | 2019-06-12 |
| Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin Vildagliptin, Metformin, sulfonylurea (SU) - Type 2 Diabetes Mellitus (T2DM) | Phase 3 | Completed | Novartis Pharmaceuticals | 42 | 2013-06-01 | 2016-04-21 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA) Lixisenatide (AVE0010), Placebo, Pen auto-injector - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Sanofi | 311 | 2009-03-01 | 2016-10-11 |
| GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin Lixisenatide (AVE0010), Placebo, Basal Insulin - Diabetes Mellitus, Type 2 | Phase 3 | Completed | Sanofi | 496 | 2008-07-01 | 2016-11-28 |
Diabetes Mellitus, Type 2 (6) · Insulin Resistance (3) · Diabetes Mellitus (2) · Hyperglycemia (2) · Diabetes Mellitus, Type 1 (1) · Respiratory Aspiration (1)
Sanofi (2) · Mannkind Corporation (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1) · Novo Nordisk A/S (1)
United States (3) · France (2) · India (2) · Mexico (2) · South Korea (2) · Argentina (1) · Brazil (1) · Canada (1) · Chile (1) · Egypt (1) · Germany (1) · Italy (1) · Japan (1) · Philippines (1) · Puerto Rico (1)
Kevin Kaiserman (1)
PMID 31956422, PMID 22564709, PMID 23628617, PMID 25130920, PMID 26039935, PMID 28345792, PMID 28857451, PMID 29802636, PMID 30547388, PMID 30614616, PMID 31064361, PMID 31797522, PMID 32236732, PMID 32324065, PMID 32324082, PMID 32372382, PMID 32648108, PMID 34213819, PMID 36763328, PMID 36809495